Bharat Biotech Plans $500 Million IPO as Vaccine Maker Seeks Stock Market Listing
Bharat Biotech International Ltd. to Explore $500 Million IPO
Bharat Biotech International Ltd., a vaccine developer founded in 1996, is reportedly considering an initial public offering (IPO) to raise $500 million. According to a Bloomberg report, discussions for the deal are ongoing, with the specifics, including the size and timing, subject to change.
The Hyderabad-based company boasts a significant portfolio, including vaccines for Covid-19 and hepatitis B, as well as treatments for burns and diarrhoea. Bharat Biotech claims to have distributed over 9 billion vaccines globally, highlighting its established presence in the industry.
This development follows a recent Technology Transfer Agreement signed between Bharat Biotech and Biofabri, a part of Zendal group in Spain, for the development of tuberculosis vaccines. The company's efforts to expand its product offerings and global reach are expected to continue, with this potential IPO serving as a crucial step in its growth strategy.
Read also: SMR Jewels IPO Successfully Lists with Institutional Support
Investor Takeaway
Investors should consider Bharat Biotech's potential for long-term growth following its planned IPO.
More in IPO
SMR Jewels IPO Successfully Lists with Institutional Support
Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO
Merritronix IPO Sees Robust Subscription, Oversubscribed by 293 Times on Final Day
